TEVA, US8816242098

Teva Pharmaceutical Industries stock gains as biosimilar deal expands

Published on 10/04/2026 at 14:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva Pharmaceutical Industries stock stood at USD 39.53 on October 2, 2026, after a 0.56 percent session gain. A new partnership covers up to six biosimilar candidates.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries stock (ISIN US8816242098) closed at USD 39.53 on the NYSE on October 2, 2026, gaining 0.56 percent as the company broadened its biosimilar pipeline. On October 1, 2026, Teva Pharmaceutical Industries announced a global license, development and commercialization agreement with Samsung Bioepis covering up to six potential biosimilar candidates.

Six candidates expand the pipeline

The agreement names SB41, a candidate referencing Fasenra, and SB44, a candidate referencing Ilaris, with an option for four additional assets. Samsung Bioepis will handle development, regulatory registration and manufacturing, while Teva will commercialize the medicines in the United States, Europe and Canada.

The arrangement gives Teva commercial rights without making the company responsible for the partners development and manufacturing work. That division matters because the agreement adds potential products while preserving Teva's role in distribution and market access.

Analysts set a higher bar

According to MarketBeat on October 1, 2026, TD Cowen initiated coverage with a Buy rating and a USD 55.00 price target. The target stands above the October 2 close of USD 39.53, making the analyst view a separate valuation benchmark rather than a company forecast.

MarketBeat also reported a Moderate Buy consensus from 13 analysts, including 12 Buy ratings and one Hold rating, with an average target of USD 44.67. The consensus target is above the October 2 close, but the range of individual views still places importance on execution across the newer pipeline.

Returns remain ahead of the market

Teva stock was up 26.66 percent year to date and 97.16 percent over the one-year period through October 2, 2026. The one-year gain is 70.50 percentage points higher than the year-to-date gain, showing that much of the longer run-up predates the latest partnership announcement.

The October 2 session traded between USD 39.05 and USD 39.81, while the 52-week range extended from USD 18.83 to USD 40.79. Teva's market capitalization stood at USD 46.1 billion, and volume reached 4,752,351 shares on the session.

Teva stock closes near its yearly high

Teva stock closed at USD 39.53 on the NYSE on October 2, 2026. The price was USD 1.26 below the 52-week high of USD 40.79, while the biosimilar agreement adds a concrete pipeline event to the valuation discussion.